Publications

Dynamic elevation of aromatic amino acids in Hepatitis C Virus induced cirrhosis after a standard meal

Hill KL, Haddad JA, Ali RO, Zhang GY, Quinn GM, Townsend E, Everson GT, Helmke SM, Bagheri M, Schoenfeld M, Yang S, Koh C, Levy EB, Kleiner DE, Sacks DB, Etzion O, Heller T. | Clinical and Translational Gastroenterology 2024;15:e00666

Advances in Noninvasive Measurement of Liver Function and Physiology: The HepQuant DuO Test

Michael P. McRae, John Kittelson, Steve M. Helmke, and Gregory T. Everson | Basic Clin Pharmacol Toxicol 2024 Jan 15. Mar;134(3):385-395

Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study

Eric J. Lawitz, Thomas Reiberger, Jörn M. Schattenberg, Corinna Schoelch, Harvey O. Coxson, Diane Wong, Judith Ertle | Hepatology Communications. 2023 Mar 0;7:e0276

Compartmental model describing the physiological basis for the HepQuant SHUNT test

Michael P. McRae, Steve M. Helmke, James R. Burton Jr., and Gregory T. Everson | Transl Res. Volume 252, P53-63, February 2023

Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt

Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, The HALT-C Trial Group (2007) | Aliment Pharmacol Ther, 26(3):401-10

HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease

Wieland A, Etzion O, Ali RO, Levy E, Kleiner D, Helmke SM, Heller T, Everson GT | Clin Gastroenterol Hepatol. 2021 Apr 22;S1542-3565(21)00464-X

Predicting clinical decompensation in patients with cirrhosis using the HepQuant SHUNT Test

Fallahzadeh MA, Hansen DJ, Trotter JF, Everson GT, Saracino G, Rahimi RS, Helmke S, Boutte J, Asrani SK | Aliment Pharmacol Ther. 2021 Apr;53(8):928-938

Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test

Maan R, Sonneveld MJ | Aliment Pharmacol Ther. 2021 Apr;53(8):939-940

Authors’ Response to “Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test”

Asrani S, Everson GT | Aliment Pharmacol Ther. 2021 Apr;53(8):941-942

How clinicians may use tests of hepatic function now and in the future

Ghaziani TT, Kwo PY | Transl Res. 2021; 233:1-4